Evidence map›Paper›PMID 36495264›Full record

ArticleJournal of the American Geriatrics Society2023

Can markers of disease severity improve the predictive power of claims-based multimorbidity indices?

Anael Rizzo, Bocheng Jing, W John Boscardin, Sachin J Shah, Michael A Steinman

Abstract read
In one paragraph

Article in Journal of the American Geriatrics Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Anael RizzoDavid Geffen School of Medicine, University of California, Los Angeles, California, USA.
Bocheng JingDivision of Geriatrics, University of California San Francisco and San Francisco VA Medical Center, San Francisco, California, USA.
W John BoscardinDivision of Geriatrics, University of California San Francisco and San Francisco VA Medical Center, San Francisco, California, USA.
Sachin J ShahSection of Hospital Medicine, Massachusetts General Hospital, Boston, MA, USA.
Michael A SteinmanDivision of Geriatrics, University of California San Francisco and San Francisco VA Medical Center, San Francisco, California, USA.ORCID 0000-0002-9564-9480

Funding

VARC CoreP30AG044281 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Louise C. Walter · 2013 to 2026
$19.9M
Unnecessary and Harmful Medication Use in Older Adults with DementiaP01AG066605 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MELISSA Diane ALDRIDGE · 2020 to 2026
$17.7M
Prescribing cascades in older adults with and without dementiaK24AG049057 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEINMAN, MICHAEL A. · 2015 to 2025
$1.8M
Creating a better index for measuring multimorbidity in older adultsR01AG052041 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI STEINMAN, MICHAEL A. · 2016 to 2018
$1.2M
NIA NIH HHS K24 AG049057NIA NIH HHS P01 AG066605NIA NIH HHS P30 AG044281NIA NIH HHS R01 AG052041
6 · The paper itself

Abstract

backgroundClaims-based measures of multimorbidity, which evaluate the presence of a defined list of diseases, are limited in their ability to predict future outcomes. We evaluated whether claims-based markers of disease severity could improve assessments of multimorbid burden.

methodsWe developed 7 dichotomous markers of disease severity which could be applied to a range of diseases using claims data. These markers were based on the number of disease-associated outpatient visits, emergency department visits, and hospitalizations made by an individual over a defined interval; whether an individual with a given disease had outpatient visits to a specialist who typically treats that disease; and ICD-9 codes which connote more versus less advanced or symptomatic manifestations of a disease. Using Medicare claims linked with Health and Retirement Study data, we tested whether including these markers improved ability to predict ADL decline, IADL decline, hospitalization, and death compared to equivalent models which only included the presence or absence of diseases.

resultsOf 5012 subjects, median age was 76 years and 58% were female. For a majority of diseases tested individually, adding each of the 7 severity markers yielded minimal increase in c-statistic (≤0.002) for outcomes of ADL decline and mortality compared to models considering only the presence versus absence of disease. Gains in predictive power were more substantial for a small number of individual diseases. Inclusion of the most promising marker in multi-disease multimorbidity indices yielded minimal gains in c-statistics (<0.001-0.007) for predicting ADL decline, IADL decline, hospitalization, and death compared to indices without these markers.

conclusionsClaims-based markers of disease severity did not contribute meaningfully to the ability of multimorbidity indices to predict ADL decline, mortality, and other important outcomes.

Indexed as

MedicareMultimorbidityAgedFemaleHospitalizationHumansMalePatient AcuityUnited Statesaginghealth and retirement studyillness severityMedicaremultimorbid burden

Identifiers

PMID36495264
PMCPMC10023343

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.